Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMTOR Study
2025-520854-12-00Phase 4Authorised
- Sponsor
- Hospital Universitario La Paz
- Start
- Jun 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus, sirolimus, mycophenolate sodium and valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Hospital Universitario La Paz. Primary endpoint: Presence of cytomegalovirus infection or disease at 6 months post-transplantation. Planned start Jun 2025; status: authorised.
02
Drugs
tacrolimussirolimusmycophenolate sodiumvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2025-520854-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520854-12-00.